Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating safety and efficacy of oral NRC-2694-A in combination with paclitaxel for recurrent and/or metastatic head and neck squam…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• NRC-2694-A
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: NATCO Pharma Ltd. | Conditions: Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING